A5025175512- Lung Cancer Treatments and Mutations
- Synthesis and biological activity
- HER2/EGFR in Cancer Research
- Cancer therapeutics and mechanisms
- Quinazolinone synthesis and applications
- Cancer Mechanisms and Therapy
- Pancreatic function and diabetes
- Pancreatic and Hepatic Oncology Research
- Phagocytosis and Immune Regulation
Hanyang University
2025
Asan Medical Center
2022-2023
University of Ulsan
2022-2023
Ulsan College
2022
Abstract Osimertinib is an irreversible third-generation EGFR tyrosine kinase inhibitor (TKI) that was initially developed to overcome the T790M mutation and used as a standard therapy in patients with advanced non–small cell lung cancer (NSCLC) EGFR-activating mutations. Despite remarkable initial efficacy, osimertinib, like other EGFR-TKIs, limited by emergence of acquired resistance. As C797S has been identified key driver resistance development drug targets this clinically relevant could...
<div>Abstract<p>Osimertinib is an irreversible third-generation EGFR tyrosine kinase inhibitor (TKI) that was initially developed to overcome the T790M mutation and used as a standard therapy in patients with advanced non–small cell lung cancer (NSCLC) EGFR-activating mutations. Despite remarkable initial efficacy, osimertinib, like other EGFR-TKIs, limited by emergence of acquired resistance. As C797S has been identified key driver resistance development drug targets this...
<div>Abstract<p>Osimertinib is an irreversible third-generation EGFR tyrosine kinase inhibitor (TKI) that was initially developed to overcome the T790M mutation and used as a standard therapy in patients with advanced non–small cell lung cancer (NSCLC) EGFR-activating mutations. Despite remarkable initial efficacy, osimertinib, like other EGFR-TKIs, limited by emergence of acquired resistance. As C797S has been identified key driver resistance development drug targets this...
Supplementary Data from The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02–011 Overcomes C797S-Mediated Resistance in Lung Cancer
Supplementary Data from The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02–011 Overcomes C797S-Mediated Resistance in Lung Cancer